Fibromyalgia

Patients with fibromyalgia have central pain amplification1
 
fMRI* Analysis: Fibromyalgia patients showing larger activation of regions of the pain network2
 
 
 
 
 
# LPD Pregabalin-Lyrica-IND-English version : 22.0.
 
References:
  1. Gracely R, Petzke F, Wolf J, Clauw G. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333-1343.
  2. Pujol J, López-Solà M, Ortiz H, et al. Mapping brain response to pain in fibromyalgia patients using temporal analysis of fMRI. PLOS ONE. 2009;4(4):e5224.
  3. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with fibromyalgia syndrome. Arthr Rheum. 1994;37(11):1593-1601.
  4. Sarchielli P, Mancini ML, Floridi A, et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain. 2007;8(9):737-745.
  5. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthr Rheum. 1992;35(5):550-556.
Please click on Prescribing Information link to view safety and adverse events information of LYRICA®.
For the use only of registered medical practitioners or a hospital or a laboratory.
Provides fast and sustained pain relief in fibromyalgia patients1,2,3
 
Pain reduction with 3 different doses3*
 
 
# LPD Pregabalin-Lyrica-IND-English version : 22.0.
 
References:
  1. Mease PJ, Russell IJ, Florian H, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35(3):502-514.
  2. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419-431.
  3. Straube S, Derry S, Moore R, McQuay H. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford). 2010;49(4):706-715.
  4. Arnold L, Emir B, Pauer L, Resnick M, Clair A. Time to improvement of pain and sleep quality in clinical trials of pregabalin for the treatment of fibromyalgia. Pain Med. 2015;16:176-185.
Please click on Prescribing Information link to view safety and adverse events information of LYRICA®.
For the use only of registered medical practitioners or a hospital or a laboratory.
Pregabalin improves fibromyalgia pain in patients taking SSRIs/SNRIs for co-morbid depression1
 
 
# LPD Pregabalin-Lyrica-IND-English version : 22.0.
 
References:
  1. Arnold LM, Sarzi-Puttini P, Arsenault P, et al. Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo controlled study. J Rheumatol. 2015;42(7):1237-44.
  2. Arnold L, Emir B, Pauer L, Resnick M, Clair A. Time to improvement of pain and sleep quality in clinical trials of pregabalin for the treatment of fibromyalgia. Pain Med. 2015;16:176-185.
Please click on Prescribing Information link to view safety and adverse events information of LYRICA®.
For the use only of registered medical practitioners or a hospital or a laboratory.
Proven efficacy in refractory patients of fibromyalgia not responding to gabapentin, SSRIs, SNRIs & TCAs1
 
Significant decrease (P<0.01) in pain severity in refractory patients of fibromyalgia1
 
# LPD Pregabalin-Lyrica-IND-English version : 22.0.
 
References:
  1. Stacey BR, Emir B, Petersel D, et al. Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J. 2010;4:35-38.
Please click on Prescribing Information link to view safety and adverse events information of LYRICA®.
For the use only of registered medical practitioners or a hospital or a laboratory.
 
Recommended as FIRST-LINE treatment across international guidelines
 
 
# LPD Pregabalin-Lyrica-IND-English version : 22.0.
 
References:
  1. American Diabetes Association. Addendum. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021: Diabetes Care 2021;44(Suppl.1):S151-S167.
  2. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;13(11):1113-1123.
  3. Ballantyne JC, Carwood CM, Giamberardino MA. Pharmacological management of neuropathic pain. Pain: Clinical Updates. 2010.
  4. Bril V, England J, Franklin G, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758-1765.
  5. Moulin D, Boulanger A, Clark AJ, et al; Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-35.
  6. Neuropathic pain – pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings. NICE clinical guideline https://www.nice.org.uk/guidance/cg173 accessed 19 August 2021.
  7. Hooten WM, Timming R, Belgrade M et al. Assessment and management of chronic pain. Institute for Clinical Systems Improvement. 2013 Nov;106.
  8. Cole BE, Argoff CE, Fishbain DA, et al. Consensus Guidelines: Assessment, Diagnosis, And Treatment of Diabetic Peripheral Neuropathic Pain. Mayo Clinic Proc. 2006;81(4 Suppl):S3-11.
Please click on Prescribing Information link to view safety and adverse events information of LYRICA®.
For the use only of registered medical practitioners or a hospital or a laboratory.

PP-LYR-IND-0225 dated 14th July, 2021